Allurion Technologies (NYSE:ALUR) received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Allurion Gastric Balloon System, marking a significant expansion into the U.S. obesity care market.
The device, known as the Allurion Smart Capsule, is a swallowable weight-loss balloon that requires no surgery, endoscopy, or anesthesia.
During a 15-minute office visit, patients swallow the capsule, which is then filled with fluid to occupy space in the stomach and induce satiety.
The device remains in the body for approximately four months before a patented release valve opens, allowing it to pass naturally.
The company is positioning the device as a "metabolically healthy" alternative to bariatric surgery and popular GLP-1 receptor agonists like Wegovy and Zepbound.
Allurion is targeting a specific gap in the weight-loss market.
The company estimates that 80 million Americans fall within the device's approved BMI range.
Crucially, Allurion is pitching the Smart Capsule to the growing number of "GLP-1 dropouts"—patients who discontinue weight-loss injections due to side effects or costs.
Company data suggests that approximately 65% of patients stop GLP-1 treatment within the first year.
The approval comes at a critical time for the Natick, Massachusetts-based company, which has been navigating a competitive landscape dominated by pharmaceutical giants.
Unlike daily or weekly medications, the Allurion system offers a discrete four-month treatment cycle from a single administration.
The company noted that a second capsule can be administered two months after the first has passed, allowing for a phased approach to weight loss.
Commercial availability in the United States is expected to follow shortly, leveraging Allurion's existing international footprint, where the device is already covered by over 50 patents.